Core Insights - Illumina reported $1.08 billion in revenue for Q3 2025, a year-over-year increase of 0.4%, with an EPS of $1.34 compared to $1.14 a year ago, exceeding both revenue and EPS estimates [1][2] Revenue Breakdown - Product revenue reached $927 million, surpassing the estimated $899.38 million, reflecting a year-over-year increase of 1.4% [4] - Service and other revenue was $157 million, below the average estimate of $165.17 million, indicating a year-over-year decline of 5.4% [4] - Consumable product revenue was $816 million, slightly above the estimated $803.8 million, marking a year-over-year increase of 1.1% [4] - Instrument product revenue was $111 million, exceeding the estimate of $105.1 million, with a year-over-year increase of 3.7% [4] - Sequencing consumables revenue was $747 million, above the estimate of $737.64 million, showing a year-over-year increase of 0.8% [4] - Sequencing instruments revenue was $107 million, slightly above the estimate of $106.24 million, with a year-over-year increase of 2.9% [4] - Microarrays consumables revenue was $69 million, close to the estimate of $69.75 million, reflecting a year-over-year increase of 4.6% [4] - Microarrays instruments revenue was $4 million, exceeding the estimate of $3.35 million, indicating a significant year-over-year increase of 33.3% [4] Stock Performance - Illumina's shares have returned -7.1% over the past month, contrasting with the Zacks S&P 500 composite's +3.6% change, and the stock currently holds a Zacks Rank 3 (Hold) [3]

Core Insights - Illumina reported revenue of $1.04 billion for the quarter ended March 2025, reflecting a 3.3% decrease year-over-year, while EPS increased to $0.97 from $0.09 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate by 0.25%, and the EPS also surpassed the consensus estimate by 1.04% [1] Revenue Breakdown - Product revenue was $880 million, slightly above the average estimate of $872.04 million, marking a year-over-year increase of 0.5% [4] - Core Illumina service and other revenue totaled $161 million, below the average estimate of $175.08 million, representing a year-over-year decline of 6.9% [4] - Total product revenue for Core Illumina was $880 million, compared to the average estimate of $869.69 million, showing a year-over-year decrease of 0.3% [4] - Service and other revenue was $161 million, below the average estimate of $170.12 million, with a significant year-over-year decline of 19.5% [4] - Sequencing instruments revenue reached $109 million, slightly above the estimated $108.51 million, reflecting a year-over-year decrease of 0.9% [4] - Core Illumina instruments revenue was $112 million, in line with the average estimate of $112.06 million, showing a year-over-year decline of 1.8% [4] - Sequencing consumables revenue was $696 million, exceeding the estimated $679.85 million, with a year-over-year decrease of 0.3% [4] - Microarrays instruments revenue was $3 million, below the estimated $3.61 million, representing a significant year-over-year decline of 25% [4] - Microarrays consumables revenue was $72 million, slightly below the average estimate of $74.59 million, with a year-over-year increase of 1.4% [4] - Overall, Core Illumina revenue was $1.04 billion, surpassing the average estimate of $1.03 billion, but reflecting a year-over-year decline of 1.4% [4] - Core Illumina consumables revenue was $768 million, exceeding the estimated $748.87 million, with a year-over-year decrease of 0.1% [4] Stock Performance - Illumina's shares returned 0.1% over the past month, compared to a 11.3% increase in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Q1 2025 Earnings Presentation May 8, 2025 © 2025 Illumina, Inc. All rights reserved. Cautionary Notes This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) changes in the rate of growth in the markets we serve; (ii) the volume, timing and mix of customer orders among our products and services; (iii) our abi ...

Core Insights - Analysts forecast Illumina (ILMN) to report quarterly earnings of $0.96 per share, reflecting a year-over-year increase of 966.7% [1] - Expected revenues are projected at $1.04 billion, indicating a decline of 3.5% compared to the same quarter last year [1] Earnings Estimates - The consensus EPS estimate has been revised downward by 0.6% in the past 30 days [2] - Revisions to earnings estimates are significant indicators for predicting investor actions regarding the stock [3] Revenue Breakdown - Analysts expect 'Revenue- Product revenue- Consumable' to be $763.09 million, showing a year-over-year change of +0.1% [5] - The estimate for 'Revenue- Service and other revenue' is $170.12 million, suggesting a decline of 14.9% year over year [5] - 'Revenue- Product revenue' is predicted to reach $872.04 million, indicating a decrease of 0.5% [5] Core Revenue Metrics - 'Revenues- Core Illumina- Service and other revenue' is expected to be $175.08 million, reflecting a year-over-year increase of 1.2% [6] - 'Revenues- Core Illumina- Total product revenue' is projected at $869.69 million, suggesting a decline of 1.5% year over year [6] Instrument and Consumable Revenue - 'Revenue- Product revenue- Instruments' is likely to be $108.95 million, indicating a change of -4.4% from the prior-year quarter [7] - 'Revenues- Core Illumina- Consumables' is expected to reach $748.87 million, reflecting a decrease of 2.6% [7] Sequencing Revenue Estimates - 'Revenue- Sequencing- Instruments' is projected at $108.51 million, indicating a change of -1.4% from the year-ago quarter [8] - 'Revenue- Sequencing- Consumables' is expected to be $679.85 million, suggesting a decline of 2.6% year over year [8] Microarrays Revenue Forecast - 'Revenue- Microarrays- Instruments' is estimated to reach $3.61 million, indicating a change of -9.9% from the prior-year quarter [9] - 'Revenue- Microarrays- Consumables' is projected at $74.59 million, reflecting a year-over-year change of +5.1% [9] - Overall, 'Revenue- Core Illumina' is expected to be $1.03 billion, indicating a decline of 2.1% year over year [9] Stock Performance - Illumina shares have returned +5% over the past month, outperforming the Zacks S&P 500 composite's +0.4% change [9] - With a Zacks Rank 3 (Hold), ILMN is expected to mirror the overall market performance in the near future [10]